Medpace Holdings reported third quarter 2026 adjusted EPS of $4.84 and revenue of $716 million, both above Zacks consensus estimates. The combination of an earnings beat and an estimated 14.3% long-term earnings growth rate highlights how Medpace Holdings is executing against demand for outsourced clinical development. We will examine how the Medpace Holdings investment narrative intersects with this earnings and revenue beat to reshape the risk-reward profile. See how Medpace Holdings’...
A best-possible 99 Composite Rating is just one reason to watch Medpace.
Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.
Medpace (MEDP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Motley Fool Press Release.
Motley Fool Press Release.
Detailed price information for Medpace Holdings Inc (MEDP-Q) from The Globe and Mail including charting and trades.
Medpace stock slipped late Wednesday despite beating third-quarter forecasts and issuing an above-Street view for 2026 earnings.
Medpace (MEDP) HOLD rating: bookings and backlog improve, but valuation is full and pass-through revenue distorts growth. Read here for more details.
Medpace is rated Sell, with a $484.49 fair value versus a $612.05 close—implying a 26.33% premium. Click to read more about the MEDP stock.
Medpace is rated a Buy with Q2 revenues rising 17.2% to $707.3M, improving EBITDA margins, and guidance raised for FY26. Read more on MEDP stock here.
Medpace (MEDP) concluded the recent trading session at $602.9, signifying a -2.84% move from its prior day's close.
Medpace Holdings (NASDAQ:MEDP) has outperformed the market over the past 10 years by 21.36% on an annualized basis producing an average annual return of 35.2%. Currently, Medpace Holdings has a market capitalization of
This is the newest page. Registered accounts read further back.